Brokerages expect Crispr Theraptc (NASDAQ:CRSP) to post ($0.60) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Crispr Theraptc’s earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at ($0.51). Crispr Theraptc posted earnings per share of ($2.77) during the same quarter last year, which would indicate a positive year-over-year growth rate of 78.3%. The business is expected to issue its next quarterly earnings results on Tuesday, November 28th.

According to Zacks, analysts expect that Crispr Theraptc will report full year earnings of ($2.46) per share for the current financial year, with EPS estimates ranging from ($2.49) to ($2.43). For the next fiscal year, analysts expect that the business will post earnings of ($3.03) per share, with EPS estimates ranging from ($3.09) to ($2.96). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Crispr Theraptc.

Crispr Theraptc (NASDAQ:CRSP) last posted its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The business’s revenue for the quarter was up 350.0% compared to the same quarter last year.

CRSP has been the topic of several research analyst reports. Cann initiated coverage on Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Barclays PLC reiterated a “buy” rating and set a $29.00 price target on shares of Crispr Theraptc in a research report on Friday, September 8th. SunTrust Banks, Inc. initiated coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Finally, Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.08.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Crispr Theraptc (CRSP) Will Announce Earnings of -$0.60 Per Share” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/11/01/zacks-brokerages-anticipate-crispr-theraptc-crsp-will-announce-earnings-of-0-60-per-share.html.

In related news, Director Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock in a transaction on Friday, August 4th. The stock was sold at an average price of $17.81, for a total value of $898,995.37. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tyler Dylan-Hyde sold 15,000 shares of Crispr Theraptc stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $18.57, for a total value of $278,550.00. Following the completion of the transaction, the insider now owns 167,727 shares in the company, valued at $3,114,690.39. The disclosure for this sale can be found here. Insiders sold a total of 444,010 shares of company stock worth $8,617,089 over the last 90 days. Insiders own 39.98% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Credit Suisse AG acquired a new stake in shares of Crispr Theraptc in the first quarter worth $1,742,000. Hershey Trust Co. acquired a new stake in shares of Crispr Theraptc in the third quarter worth $768,000. Vanguard Group Inc. acquired a new stake in shares of Crispr Theraptc in the second quarter worth $273,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Crispr Theraptc in the third quarter worth $235,000. Finally, ARK Investment Management LLC acquired a new stake in shares of Crispr Theraptc in the second quarter worth $206,000. Institutional investors and hedge funds own 25.50% of the company’s stock.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Theraptc (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.